The Microbiome and Treatment Response

The gut microbiome communicates with the immune system, produces metabolites, influences inflammation, and may affect treatment response, especially in the setting of immunotherapy. Research is promising but still evolving (Kang et al., Cell Reports Medicine, 2024).

Studies suggest that microbiome patterns can correlate with response and toxicity in some patients receiving immune checkpoint inhibitors. However, microbiome testing is not yet a universal decision-making tool for all cancer patients (Gazzaniga et al., Journal of Clinical Investigation).

A diverse, plant-forward diet with adequate protein may support microbial diversity, but recommendations must change when patients have diarrhea, bowel surgery, obstruction risk, mucositis, neutropenia precautions, or treatment-related digestive changes.

Probiotics are not automatically safe or appropriate for every oncology patient. Immune status, central lines, blood counts, infection risk, and treatment type should be considered.

SANAVITA Health provides physician-led integrative oncology education and support with a focus on clarity, safety, whole-person care, and collaboration. The goal is to help patients understand their options, reduce avoidable risk, and build a supportive plan that fits their diagnosis, treatment phase, values, and care team recommendations.